Levetiracetam in newly-diagnosed epilepsy: KOMET trial results February 27, 2013 Recommend to a Colleague print Levetiracetam does not show superiority over standard agents for patients newly-diagnosed with epilepsy, according to the results of the KOMET trial. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue
